At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy During Recover From Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
In Brief
A Phase 2 clinical trial evaluating TTRNA-xALT and TTRNA-DCs for Medulloblastoma and Neuroectodermal Tumor. Completed, enrolled 26 participants across 3 sites.
Detailed Summary
Immunotherapy is a specific approach to treating cancer that has shown promise in adult patients for the treatment of melanoma, malignant brain tumors, and other cancers. The study investigators will use the experience they have gained from these studies to try to improve the outcome for children affected by a recurrent brain tumor. Approximately 35 patients with first recurrence of medulloblastoma (reMB)/supratentorial primitive neuroectodermal tumors (PNETs) will be treated with tumor-specific immune cells and dendritic cell vaccines to see what impact they have on the tumor.
Study Details
Timeline
Interventions
TTRNA-xALT 3 x 10\^7/kg by intravenous injection once.
TTRNA-DCs 1 x 10\^7 by intradermal injection every 2 weeks for 3 total doses.